Results 81 to 90 of about 13,727 (197)
Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure
The current paradigm of medical therapy for heart failure with reduced ejection fraction (HFrEF) is triple neurohormonal blockade with an angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB) and a mineralocorticoid receptor antagonist (MRA)
J. Silva-Cardoso +10 more
doaj +1 more source
Importance The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril.
Chan, Wing W. +9 more
core +1 more source
Sacubitril/valsartan: um importante avanço no puzzle terapêutico da insuficiência cardíaca
Resumo: O sacubitril/valsartan (LCZ696) é um complexo supramolecular de sal de sódio do pró‐fármaco sacubitril, inibidor da neprilisina, e do valsartan, um antagonista dos recetores da angiotensina (ARB), administrado por via oral, recentemente aprovado ...
Pedro Marques da Silva, Carlos Aguiar
doaj +1 more source
Background: Recent studies reported an abbreviation of cardiac repolarization induced by sacubitril. Thus, the purpose of this study was to evaluate the electrophysiologic effects of sacubitril in the presence of drugs that shorten the QT interval ...
Christian Ellermann +7 more
doaj +1 more source
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou +6 more
wiley +1 more source
Improving Postdischarge Outcomes in Acute Heart Failure [PDF]
The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P. +8 more
core +1 more source
ABSTRACT One of the most serious complications associated with the use of the chemotherapeutic agent doxorubicin (DOX) is cardiomyopathy. Although cardioprotective drugs such as angiotensin receptor‐neprilysin inhibitors (ARNI) are used to prevent cardiomyopathy in DOX patients, no studies have reported the relationship between ARNI and endoplasmic ...
Mert Unvan +3 more
wiley +1 more source
Molecular Implications of natriuretic peptides in the protection from hypertension and target organ damage development [PDF]
The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure levels, in turn, concur with the development of cardiovascular damage.
Forte, Maurizio +3 more
core +1 more source
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang +22 more
wiley +1 more source
Declining risk of sudden death in heart failure [PDF]
No abstract ...
Jhund, Pardeep S. +2 more
core +1 more source

